(Q30596342)

English

Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 August 2017

Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS). (English)

1 reference

Europe PubMed Central

21 August 2017

1 reference

based on heuristic

inferred from title

object named as

Marc Colombel

9

0 references

3

object named as

Mark Soloway

1 reference

Europe PubMed Central

21 August 2017

author name string

J Alfred Witjes

1

1 reference

Europe PubMed Central

21 August 2017

Joan Palou

2

1 reference

Europe PubMed Central

21 August 2017

Donald Lamm

4

1 reference

Europe PubMed Central

21 August 2017

Ashish M Kamat

5

1 reference

Europe PubMed Central

21 August 2017

Maurizio Brausi

6

1 reference

Europe PubMed Central

21 August 2017

Raj Persad

7

1 reference

Europe PubMed Central

21 August 2017

Roger Buckley

8

1 reference

Europe PubMed Central

21 August 2017

Andreas Böhle

10

1 reference

Europe PubMed Central

21 August 2017

publication date

1 March 2013

1 reference

Europe PubMed Central

21 August 2017

BJU International

1 reference

Europe PubMed Central

21 August 2017

112

1 reference

Europe PubMed Central

21 August 2017

6

1 reference

Europe PubMed Central

21 August 2017

742-750

1 reference

Europe PubMed Central

21 August 2017

A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933735

14 July 2018

Quality of care in patients with bladder cancer: a case report?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933735

14 July 2018

Compliance with guidelines for patients with bladder cancer: variation in the delivery of care

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933735

14 July 2018

Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933735

14 July 2018

Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and [...]

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933735

14 July 2018

An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933735

14 July 2018

Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933735

14 July 2018

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933735

14 July 2018

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933735

14 July 2018

Maintenance Bacillus Calmette-Guerin for Ta T1 Bladder Tumors Is Not Associated with Increased Toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933735

14 July 2018

1999 American Urological Association Gallup Survey: changes in physician practice patterns, treatment of incontinence and bladder cancer, and impact of managed care

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933735

14 July 2018

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12012

21 January 2018

Are referral centers for non-muscle-invasive bladder cancer compliant to EAU guidelines? A report from the vesical antiblastic therapy Italian study.

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12012

21 January 2018

Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey.

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12012

21 January 2018

Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis.

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12012

21 January 2018

Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12012

21 January 2018

Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.

1 reference

https://api.crossref.org/works/10.1111%2FBJU.12012

21 January 2018

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3933735

26 November 2018

Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/23452187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/23452187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Practical guideline for the management of adverse events associated with BCG installations]

1 reference

https://pubmed.ncbi.nlm.nih.gov/23452187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is maintenance Bacillus Calmette-Guérin really necessary?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23452187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23452187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables

1 reference

https://pubmed.ncbi.nlm.nih.gov/23452187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/BJU.12012

1 reference

Europe PubMed Central

21 August 2017

1 reference

Europe PubMed Central

21 August 2017

1 reference

Europe PubMed Central

21 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30596342&oldid=1755877503"